BIODESIX INC (BDSX)

Insider Trading Filed: 2026-04-02

Insider John Patience, the Chairman, acquired 1,361 shares of Biodesix Inc. (BDSX) through the vesting of restricted stock units on March 31, 2026.
Patience also holds significant indirect beneficial ownership of Biodesix's common stock through Patience Enterprises LP and the John Patience Living Trust, indicating his sizable stake in the company.
The restricted stock units vest in four equal installments throughout 2026, suggesting Patience's continued commitment to Biodesix's long-term success.

Annual Report Filed: 2026-02-26

The company reported a significant increase in revenue, driven by strong growth in its diagnostic tests business.
Margins have been under pressure due to rising costs, which could impact profitability going forward.
The company has secured a new licensing agreement with BioRad, which could expand its product portfolio and open up new market opportunities.

Current Report Filed: 2026-02-26

Biodesix reported Q4 and full-year 2025 financial results, showing revenue growth and improved profitability compared to the prior year.
The company did not provide any forward-looking guidance for 2026, which could indicate uncertainty about future performance.
No material changes to the company's leadership or significant business developments were reported in this 8-K filing.

Insider Trading Filed: 2026-01-27

Jack W. Schuler, an Emeritus Director of BIODESIX INC, has been actively purchasing the company's stock, acquiring a total of 100,000 shares in two separate transactions at weighted average prices of $11.8084 and $11.8032.
Schuler's purchases have increased his total beneficial ownership in the company, with 1,563,210 shares held directly through the Jack W. Schuler Living Trust and an additional 750,000 shares held indirectly through the Jack W. Schuler 2025 GRAT.
The reported transactions suggest Schuler's confidence in the company's prospects and potential future growth, which could be a positive signal for other investors.

Insider Trading Filed: 2026-01-26

Jack W. Schuler, an Emeritus Director of BIODESIX INC, acquired 82,465 shares of the company's common stock on January 22, 2026 at a weighted average price of $10.9569 per share.
In addition to the direct share acquisition, Schuler also holds an indirect beneficial ownership of 1,463,210 shares through the Jack W. Schuler Living Trust and 750,000 shares through the Jack W. Schuler 2025 GRAT.
Insider buying, especially by a director, can be a positive signal for investors as it indicates confidence in the company's prospects.

Insider Trading Filed: 2026-01-20

Chris Vazquez, the Chief Accounting Officer of BIODESIX INC, acquired 219 shares of common stock through the vesting of restricted stock units (RSUs) on January 15, 2026.
Vazquez then sold 83 shares on January 16, 2026 at a weighted average price of $8.1493 to cover taxes, leaving him with a direct ownership of 1,072 shares.
The transactions were part of a planned sale arrangement under Rule 10b5-1, indicating a systematic approach to managing equity compensation.

Insider Trading Filed: 2026-01-20

The Chief Development Officer, Gary Pestano, exercised 805 restricted stock units (RSUs) and sold 298 shares to cover taxes, indicating ongoing insider engagement and alignment with the company's performance.
The reported transactions represent a relatively small portion of Pestano's total beneficial ownership, which remains at 8,446 shares following the reported transactions.
The sale price of $8.15 per share is within a reasonable range, suggesting the transactions were conducted in the normal course of business.

Insider Trading Filed: 2026-01-20

Kieran O'Kane, the Chief Commercial Officer of Biodesix Inc., exercised 805 restricted stock units and sold 298 shares to cover taxes, indicating ongoing insider activity.
The shares were sold at a weighted average price of $8.1493, which could provide insight into the current market valuation of the company's stock.
The transaction was conducted pursuant to a Rule 10b5-1 trading plan, suggesting a pre-determined strategy for insider selling.

Insider Trading Filed: 2026-01-20

Scott Hutton, the President and CEO of Biodesix Inc., acquired 2,633 shares of the company's common stock through the vesting of restricted stock units (RSUs), and subsequently sold 970 shares to cover taxes.
Hutton's total beneficial ownership of Biodesix shares decreased from 39,944 to 38,974 shares as a result of the reported transactions.
The sale of shares to cover taxes is a common practice for executives receiving equity compensation, and the overall reduction in Hutton's ownership is relatively small, suggesting no major changes in his investment in the company.

Insider Trading Filed: 2026-01-20